Background Parenchymal Enhancement at Contrast-Enhanced Spectral Mammography (CESM) as a Breast Cancer Risk Factor
This study included 516 women who underwent CESM imaging for screening and diagnostic purposes between 2012 and 2015 in a single center. BPE at CESM images was retrospectively, independently and blindly graded by six experienced radiologists using the following scale: minimal, mild, moderate, or marked. Agreement between readers was estimated using Kendall's W coefficient of concordance. Associations between clinical factors and BPE, and between BPE and breast cancer were examined using generalized estimating equations. Association between BPE and breast cancer was assessed for the whole study group, and for the screening population separately.ResultsMost women underwent CESM for breast cancer screening (424/516, 82.2%). Mean age was 53 years, the majority had dense breasts (50.4–94%, depending on the reviewer), and minimal to mild BPE (75.8–89.9%). A total of 53/516 women had breast cancer. Overall concordance (W) values between the readers were 0.611 for breast density and 0.789 on BPE. Increased breast density and younger age were positive predictors for increased BPE (odds ratio [OR] 4.07, 95% confidence interval [CI] 2.32–7.14, p
This study evaluated compliance and implementation of these recommendations.MethodsA database of patients undergoing breast cancer surgery was retrospectively queried from 2002-2017. Patients were divided into cohorts before and after the year of each guideline publication.ResultsThe rate of presentation on mammography was not different before 2009 (65%) vs. after 2009 (66%). RT was given to 57% of patients with T1 ER+Her2- prior to 2013 vs. 27% after (p=
ConclusionThe results showed lower incremental costs of DBT vs. DM, compared to what is found in previous cost analyses of DBT and DM. However, the incremental costs were still higher for DBT compared with DM after including recall costs. Further studies with long-term treatment data are needed to understand the complete costs of implementing DBT in screening.
Worldwide breast cancer is the leading type of cancer in women . However, 99 percent of women whose breast cancer was detected early (stage 1 or 0) survive beyond five years after diagnosis . Indeed, when detected in good time, its treatment allows women to have a good prognosis reducing the rate of mortality and the incidence of surgery, radiation therapy and oncologic treatments . Mammography is the most widely used technique in screening programs to detect breast cancer at a very early stage [4,5], but it is not a perfect procedure.
ConclusionPLM plays an important role in the evaluation of patients undergoing breast conservation for breast cancer presenting with microcalcifications. Residual malignancy was detected on positive PLM in 6% of patients with negative margins.
Conclusion: 18F-FDG PET/CT revealed previously unsuspected distant metastases in 16% of male patients with pre-PET/CT stage IIB breast cancer and 33% of those with stage III breast cancer. These rates are comparable to previously published upstaging rates in female patients. 18F-FDG PET/CT demonstrates value for systemic staging of male patients with breast cancer and should be considered for use in newly diagnosed patients, particularly those with stage IIB and III disease.
Normally, when a physician notices a suspicious mass or lesion on a mammogram, he or she will request an ultrasound to explore it further. Based on those results, a biopsy may be performed to determine whether the mass is cancerous. âUnfortunately, right now, in some cases, physicians either overdiagnose or underdiagnose based on that biopsy, because with ultrasound they can only see so much,â said Lori Chmura, CEO of Dune Medical Devices. âThe doctor is essentially going in blindly, trying to see what looks like the most suspicious area, and theyâre t...
Authors: Jaiswal K, Hull M, Furniss AL, Doyle R, Gayou N, Bayliss E Abstract Background: Timely detection and treatment of breast cancer is important in optimizing survival and minimizing recurrence. Given disparities in breast cancer outcomes based on socioeconomic status, we examined time to diagnosis and treatment in a safety-net hospital. Methods: We conducted a retrospective review of all patients with breast cancer diagnosed between July 1, 2010, and June 30, 2012 (N=120). We limited our analytic sample to patients with nonrecurrent, primary stage 0-III breast cancer (N=105) and determined intervals from pres...
In conclusion, sufficient evidence is now available to suggest that breast conservation after neoadjuvant chemotherapy is safe and effective for selected patients. Though neoadjuvant chemotherapy may increase the complexity of breast conservative treatment, a close collaboration between a multidisciplinary team and use of oncoplastic surgical techiques permit to optimize oncological and cosmetis outcomes. PMID: 30352955 [PubMed - in process]
Although women may be increasingly choosing mastectomy as a breast cancer treatment,...Read more on AuntMinnie.comRelated Reading: Fewer high-risk women get mammography after USPSTF change Is radiation therapy warranted for DCIS postlumpectomy? Breast cancer follow-up imaging varies widely Biopsy rate is low after breast cancer What's the best way to follow up breast cancer survivors?
Differentiating which screen-detected breast cancers have no detrimental health effect versus those that will progress to a more advanced stage is not possible. There is no consistent method for predicting which untreated cancers would be lethal or increase in size rapidly, or the converse. More advanced stage at diagnosis of clinically detected cancers versus mammogram-detected cancers results in more aggressive surgery, chemotherapy, and radiation therapy, with a lower 5-year survival . Earlier stage cancer at diagnosis correlates with reduced breast cancer mortality .